Synergistic effects of cisplatin and proteasome inhibitor bortezomib on human bladder cancer cells

Konac,Ece; Varol,Nuray; Kiliccioglu,Ilker; Bilen,Cenk   Y.

doi:10.3892/ol.2015.3250

Synergistic effects of cisplatin and proteasome inhibitor bortezomib on human bladder cancer cells

Authors:
- Ece Konac
- Nuray Varol
- Ilker Kiliccioglu
- Cenk Y. Bilen
View Affiliations

Affiliations: Department of Medical Biology and Genetics, Faculty of Medicine, Gazi University, Ankara 06500, Turkey, Department of Urology, Faculty of Medicine, Hacettepe University, Ankara 06100, Turkey
Published online on: May 20, 2015 https://doi.org/10.3892/ol.2015.3250
Pages: 560-564

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The proteasome inhibitor bortezomib is a promising novel agent in bladder cancer therapy; however, inducible cytoprotective mechanisms may limit its potential efficacy. To date, the cellular and molecular effects of proteasome inhibitors on bladder cancer cells have been poorly characterized. Despite the consistent rate of initial responses, cisplatin treatment typically results in the development of chemoresistance, leading to therapeutic failure. Therefore, the present study aimed to characterize the molecular mechanisms underlying the anti‑proliferative effects of cisplatin and bortezomib combination therapy on the human T24 bladder cancer cell line, by analyzing the protein expression levels of apoptotic genes. Cytotoxic effects were measured using a water‑soluble tetrazolium salt‑1 assay, and the apoptosis‑associated molecules were examined using western blot analysis and ELISA. It was observed that combined administration of cisplatin and bortezomib induced upregulation of caspase‑3, ‑8 and ‑9, B‑cell lymphoma‑2 (Bcl‑2)‑like 11 and Bcl‑2‑interacting killer, but downregulated Bcl‑2 and Bcl‑extra large protein expression levels in T24 cells in a dose-dependent manner. Furthermore, enhanced protein expression of caspase‑8 and ‑9, in line with the significantly increased caspase‑3 activation, was detected when the cells were treated with a combination of cisplatin and bortezomib, compared with that of either agent alone. Bortezomib appeared to synergize with cisplatin to promote apoptosis via the extrinsic and intrinsic apoptotic pathways. Taken together, the results of the current study provide the preclinical framework for additional evaluation of the effects of combining bortezomib with other agents to induce apoptosis in bladder cancer cells.

View Figures

View References

1	Latini DM, Lerner SP, Wade SW, Lee DW and Quale DZ: Bladder cancer detection, treatment and outcomes: Opportunities and challenges. Urology. 75:334–339. 2010. View Article : Google Scholar : PubMed/NCBI
2	da Silva GN, de Castro Marcondes JP, de Camargo EA, da Silva Passos Júnior GA, Sakamoto-Hojo ET and Salvadori DM: Cell cycle arrest and apoptosis in TP53 subtypes of bladder carcinoma cell lines treated with cisplatin and gemcitabine. Exp Biol Med. 235:814–824. 2010. View Article : Google Scholar
3	Yu HM and Wang TC: Mechanism of cisplatin resistance in human urothelial carcinoma cells. Food Chem Toxicol. 50:1226–1237. 2012. View Article : Google Scholar : PubMed/NCBI
4	Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, Castedo M and Kroemer G: Molecular mechanisms of cisplatin resistance. Oncogene. 31:1869–1883. 2012. View Article : Google Scholar : PubMed/NCBI
5	Köberle B, Tomicic MT, Usanova S and Kaina B: Cisplatin resistance: Preclinical findings and clinical implications. Biochim Biophys Acta. 1806:172–182. 2010.PubMed/NCBI
6	Cho HJ, Kim JK, Kim KD, et al: Upregulation of Bcl-2 is associated with cisplatin-resistance via inhibition of Bax translocation in human bladder cancer cells. Cancer Lett. 237:56–66. 2006. View Article : Google Scholar : PubMed/NCBI
7	Li C, Li R, Grandis JR and Johnson DE: Bortezomib induces apoptosis via Bim and Bik up-regulation and synergizes with cisplatin in the killing of head and neck squamous cell carcinoma cells. Mol Cancer Ther. 7:1647–1655. 2008. View Article : Google Scholar : PubMed/NCBI
8	Al-Eisawi Z, Beale P, Chan C, Yu JQ and Huq F: Carboplatin and oxaliplatin in sequenced combination with bortezomib in ovarian tumour models. J Ovarian Res. 6:782013. View Article : Google Scholar : PubMed/NCBI
9	Chen D, Frezza M, Schmitt S, Kanwar J and Dou QP: Bortezomib as the first proteasome inhibitor anticancer drug: Current status and future perspectives. Curr Cancer Drug Targets. 11:239–253. 2011. View Article : Google Scholar : PubMed/NCBI
10	Hutter G, Rieken M, Pastore A, Weigert O, Zimmermann Y, Weinkauf M, Hiddemann W and Dreyling M: The proteasome inhibitor bortezomib targets cell cycle and apoptosis and acts synergistically in a sequence dependent way with chemotherapeutic agents in mantle cell lymphoma. Ann Hematol. 91:847–856. 2012. View Article : Google Scholar : PubMed/NCBI
11	Yang TM, Barbone D, Fennell DA and Broaddus VC: Bcl-2 family proteins contribute to apoptotic resistance in lung cancer multicellular spheroids. Am J Respir Cell Mol Biol. 41:14–23. 2009. View Article : Google Scholar : PubMed/NCBI
12	Konac E, Varol N, Yilmaz A, Menevse S and Sozen S: DNA methyltransferase inhibitor-mediated apoptosis in the Wnt/β-catenin signal pathway in a renal cell carcinoma cell line. Exp Biol Med (Maywood). 238:1009–1016. 2013. View Article : Google Scholar : PubMed/NCBI
13	Kamat AM, Karashima T, Davis DW, Lashinger L, Bar-Eli M, Millikan R, Shen Y, Dinney CP and McConkey DJ: The proteasome inhibitor bortezomib synergizes with gemcitabine to block the growth of human 253JB-V bladder tumors in vivo. Mol Cancer Ther. 3:279–290. 2004.PubMed/NCBI
14	Papageorgiou A, Kamat A, Benedict WF, Dinney C and McConkey DJ: Combination therapy with IFN-alpha plus bortezomib induces apoptosis and inhibits angiogenesis in human bladder cancer cells. Mol Cancer Ther. 5:3032–3041. 2006. View Article : Google Scholar : PubMed/NCBI
15	Qi W, White MC, Choi W, Guo C, Dinney C, McConkey DJ and Siefker-Radtke A: Inhibition of inducible heat shock protein-70 (hsp72) enhances bortezomib-induced cell death in human bladder cancer cells. PLoS One. 8:e695092013. View Article : Google Scholar : PubMed/NCBI
16	Yerlikaya A, Altıkat S, Irmak R, Cavga FZ, Kocacan SA and Boyaci I: Effect of bortezomib in combination with cisplatin and 5 fluorouracil on 4T1 breast cancer cells. Mol Med Rep. 8:277–281. 2013.PubMed/NCBI
17	Fribley AM, Evenchik B, Zeng Q, Park BK, Guan JY, Zhang H, Hale TJ, Soengas MS, Kaufman RJ and Wang CY: Proteasome inhibitor PS-341 induces apoptosis in cisplatin-resistant squamous cell carcinoma cells by induction of Noxa. J Biol Chem. 281:31440–31447. 2006. View Article : Google Scholar : PubMed/NCBI
18	Brozovic A, Ambriović-Ristov A and Osmak M: The relationship between cisplatin-induced reactive oxygen species, glutathione, and BCL-2 and resistance to cisplatin. Crit Rev Toxicol. 40:347–359. 2010. View Article : Google Scholar : PubMed/NCBI
19	Rabik CA and Dolan ME: Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev. 33:9–23. 2007. View Article : Google Scholar : PubMed/NCBI
20	Hyman BT and Yuan J: Apoptotic and non-apoptotic roles of caspases in neuronal physiology and pathophysiology. Nat Rev Neurosci. 13:395–406. 2012. View Article : Google Scholar : PubMed/NCBI
21	Kim SY, Song X, Zhang L, Bartlett DL and Lee YJ: Role of Bcl-xL/Beclin-1 in interplay between apoptosis and autophagy in oxaliplatin and bortezomib-induced cell death. Biochem Pharmacol. 88:178–188. 2014. View Article : Google Scholar : PubMed/NCBI
22	Krętowski R, Borzym-Kluczyk M and Cechowska-Pasko M: Efficient induction of apoptosis by proteasome inhibitor: Bortezomib in the human breast cancer cell line MDA-MB-231. Mol Cell Biochem. 389:177–185. 2014. View Article : Google Scholar : PubMed/NCBI
23	Elkholi R, Floros KV and Chipuk JE: The role of BH3-only proteins in tumor cell development, signaling, and treatment. Genes Cancer. 2:523–537. 2011. View Article : Google Scholar : PubMed/NCBI
24	Fennell DA, Chacko A and Mutti L: BCL-2 family regulation by the 20S proteasome inhibitor bortezomib. Oncogene. 27:1189–1197. 2008. View Article : Google Scholar : PubMed/NCBI
25	Neutzner A, Li S, Xu S and Karbowski M: The ubiquitin/proteasome system-dependent control of mitochondrial steps in apoptosis. Semin Cell Dev Biol. 23:499–508. 2012. View Article : Google Scholar : PubMed/NCBI